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Background. Sarcopenia is the presence of low muscle mass and low muscle function. The aim of this study was to establish cutoffs
for low muscle mass using three published methods and to compare the prevalence of sarcopenia in older Australians. Methods.
Gender specific cutoffs levels were identified for lowmuscle mass using three different methods. Low grip strength was determined
using established cutoffs of <30 kg for men and <20 kg for women to estimate the prevalence of sarcopenia. Results.Gender specific
cutoffs levels for lowmuscle mass identified were (a) <6.89 kg/m2 for men and <4.32 kg/m2 for women, <2 standard deviation (SD)
of a young reference population; (b) <7.36 kg/m2 for men and <5.81 kg/m2 for women from the lowest 20% percentile of the older
group; and (c) <–2.15 for men and <–1.42 for women from the lowest 20% of the residuals of linear regressions of appendicular
skeletal mass, adjusted for fat mass and height. Prevalence of sarcopenia in older (65 years and older) people by these threemethods
for men was 2.5%, 6.2%, and 6.4% and for women 0.3%, 9.3%, and 8.5%, respectively. Conclusions. Sarcopenia is common but
consensus on the best method to confirm low muscle mass is required.
1. Introduction
Sarcopenia commonly affects older people and is character-
ized by loss of both muscle mass and strength [1, 2]. Sarcope-
nia is associated with disability, a loss of independence, and
reduced quality of life [3]. In one American study, sarcopenia
and its consequenceswere estimated to cost theUS healthcare
systemUS$18 billion [4]. Sarcopenia is therefore a costly issue
to the healthcare system [4, 5].
The European Working Group on Sarcopenia in Older
People (EWGSOP) has recently defined sarcopenia as a
combination of both low muscle mass and low muscle
function [1]. Grip strength is one method to assess muscle
function [1]. Low grip strength cutoffs of <30 kg for men
and <20 kg for women are recommended and derived from
receiver operating characteristic (ROC) curves predicting
walking speeds slower than 0.8m/s [6]. Appendicular skele-
tal muscle mass (ASM) is commonly assessed using dual
absorptiometry X-ray assessment (DXA). The EWGSOP
identifies three different methods to define low muscle mass
[1]. With the oldest method, gender specific cut-off values
for low muscle mass are derived from a younger reference
group (<2 standard deviation, age 18–40 years) and cut-off
values of <7.26 kg/m2 for men and <5.50 kg/m2 for women
were reported in the original paper [2]. With the second
method, cut-off points for low muscle mass are derived from
gender specific lowest 20% of a predictive population, thus
circumventing the need for a younger reference group [7].
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Cut-off points similar to those identified by the Newman
and colleagues have been reported, <7.23 kg/m2 for men and
<5.67 kg/m2 for women [7, 8]. The third method adjusts for
fat mass and is derived from the gender specific lowest 20%
of the distribution of residuals of the linear regression on
appendicular lean mass adjusted for fat mass and height and
cutoffs of <−2.29 kg for men and <−1.73 kg for women are
reported [7].
To date, there have only been three studies in Australia
investigating the prevalence of low muscle mass but only
one has reported on the prevalence of sarcopenia (i.e., low
muscle mass and lowmuscle strength) in the community [9–
11]. Scott et al. reported a 5%prevalence of sarcopenia in those
aged 50–79 years and using the lowest 20% distribution of
the predictive population to identify the cut-off points for
both low muscle mass and low grip strength [9]. In a second
Australian study, cut-off points of <4.85 kg/m2 derived from
a young reference group were used to identify that 3.2% of
older women residing in low level aged care have sarcopenia
[10]. The third Australian study examined the prevalence of
low ASM in older (≥70 years) men living in the community
using the linear regression and the gender specific lowest 20%
method and reported a prevalence rate ranging from 15% in
those aged 70 to 74 years to 26% for those aged 80–84 years
and increasing to 45% for those aged 85–89 years [11].
To date, no study in Australia has examined the preva-
lence of sarcopenia in both men and women and compared
all three methods to identify low muscle mass. The aims
of this study were to firstly establish gender specific cut-off
points for low skeletal muscle mass using the three methods
as identified by the EWGSOP and then report the prevalence
of sarcopenia in older (aged 65 years and older) Australians
living in the community.
2. Methods
2.1. Study Cohorts. Three cohorts were investigated in this
study:TheCytokine, Adiposity, Sarcopenia and Ageing Study
(CASA), the North West Adelaide Health Study (NWAHS),
and the Florey Adelaide Male Ageing Study (FAMAS) [12–
14]. The three cohorts were combined to derive two broad
population groups: younger reference population (aged 18–
40 years; CASA and FAMAS) and older group (aged ≥65;
FAMAS and NWAHS) (see Figure 1). For the purpose of
this study, only those participants with a complete set of
information on weight, height, grip strength, and DXA were
included in the analysis.
The methodology of recruitment was similar for all three
cohorts and has been described in detail elsewhere [12–14].
Ethical approval was obtained from the Central Northern
Adelaide Health Service Ethics of Human Research Commit-
tee. All participants in the three cohort studies provided writ-
ten, informed consent. Briefly, all households in the northern
and western region of Adelaide with a telephone number
listed in the ElectronicWhite Pages were eligible for selection
into the study. Selected households were sent an approach
letter and brochure informing them about the study. The
person who was last to have a birthday and aged 18 years or
older was invited to participate in a short telephone inter-
view. Interviews were conducted using computer-assisted
telephone interview (CATI) technology. Selected persons
were deemed “nonreplaceable” and, if the selected personwas
not available, interviews were not conducted with alternative
household members. Up to six telephone calls were made to
each household before the selected individual was classified
as noncontactable. Respondents to the telephone interview
were asked a number of health-related and demographic
questions. Following the recruitment interview, respondents
were invited to make an appointment to attend clinic for
biomedical examination and investigations.
NWAHS. 4060 adults were included in the baseline biomed-
ical examination between December 1999 and July 2003.
3566 participants attended the followup (median 4 years)
between May 2004 and February 2006. Of these, a total of
1553 participants aged 65 years and older (men = 724, women
= 829) were included in the analysis [12].
FAMAS. 1195 community dwelling men aged between 35
and 80 years from the north west regions of Adelaide were
recruited between August 2002 and April 2005. Of these, 295
men were aged 65 years and older [13].
CASA. Healthy subjects aged 18 to 83 years (𝑛 = 195) were
recruited from the western suburbs of Adelaide (2005–mid-
2007). In this study, as the aim was to recruit a “healthier”
population and so there were additional criteria. To partic-
ipate in this study, subjects had to be 18 years and older,
be able to comply with the study protocol, and be weight
stable over the preceding three months. Those with a serious
medical illness, inflammatory disease, an acute illness in the
previous three months or in the two weeks following blood
sampling, unable to stop medications for three days prior to
blood sampling, in receipt of vaccinations, and pregnant were
excluded from the study [14].
2.2. Measurements
Anthropometry. Height (m) was measured with shoes off to
the nearest 0.1 cm. Weight (kg) was measured wearing light
clothing to the nearest 0.1 kg. Bodymass index (BMI, weight/
height2) was calculated.Threemeasurements of the waist and
hip were taken and the mean for each was calculated [12].
Grip Strength. Grip strength (kg) was measured three times
with each dominant hand using a grip dynamometer
(Lafayette Instrument Company, IN, USA [CASA and
NWAHS], Smedley, Chicago, IL [FAMAS]) while subjects
were sitting with their arm supported by a horizontal surface.
The mean of the three readings was used in this study [15].
Dual Energy X-Ray Absorptiometry (DXA). Appendicular
skeletal muscle mass (ASM) in this study was defined as the
sum of lean soft-tissue masses for arms and legs, assuming
that all nonfat and nonbone tissue are skeletal muscle. CASA:
ASM was determined using a Lunar PRODIGY whole-body
scanner (GE Medical Systems, Madison, WI) in conjunction
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Men, n = 117
Women, n = 78
Men, n = 137
Women, n = 23
Men, n = 23
Women, n = 0
Men, n = 114
Women, n = 23
Men, n = 724
Women, n = 829
Men, n = 784
Women, n = 521
Men, n = 1195
participants§
Excluded 
Men, n = 173
Women, n = 146
participants§
data∗ (final cohort)
Participants with completed 
Men, n = 611
Women, n = 375
data∗ (final cohort)
∗Completed data = those with completed measurements of DXA, grip strength, and anthropometric measurements (weight and height) 
§Missing either one or more of the components of DXA, grip strength, and anthropometric measurements
Community dwelling men aged 35–80 years
Figure 1: Cohorts combined to develop the younger reference (aged 18–<40) and older study group (aged 65+).
with Encore 2002 software. NWAHS and FAMAS: A Lunar
PRODIGY scanner (GE Medical Systems, Madison, WI) in
conjunction with Encore 2002 software and a DPX+ (GE
Medical Systems, Madison, WI) scanner in conjunction with
LUNAR software version 4.7e were used. Cross-calibration
analysis reported no significant differences between the 2
machines [16].
2.3. Statistical Analysis. SPSS 19 forWindows software (SPSS,
Inc., Chicago, IL) was used for statistical analysis. Descriptive
data was expressed as mean ± standard deviation (SD).
Independent two-sample t-test was used to assess the mean
difference in the characteristics variables between men and
women. Low muscle mass was identified using the three
different methods: (a) Baumgartner’s method whereby cut-
off values of ASMwere <2 standard deviation (SD) of a young
reference population, (b) the 20% gender specific method
where cutoffs were derived for the lowest 20% of the older
study population, and (c) the linear regressionmethod where
the lowest 20% of residual of the linear regression models of
ASM adjusting for fat mass and height in men and women
were applied to the older study population to derive cut
points. As walk speed was not available within the NWAHS
cohort, grip strength was used to determine muscle function
and cutoffs of <30 kg for men and <20 kg for women were
applied [6]. 𝑃 < 0.05 was considered statistically significant.
3. Results
Figure 1 illustrates the flow diagram in establishing the two
study populations from the three cohorts. For the young
reference group, from the CASA and FAMAS cohort, there
were a total of 137 men and 23 women aged 18–40 years.
Of these, 23 men were excluded because of insufficient data.
There were no statistically significant differences between the
original and final cohorts in terms of age (35.7 ± 4.9 versus
35.5 ± 5.3 years, 𝑃 = 0.75), weight (88.0 ± 16.3 versus
87.7 ± 15.9 kg, 𝑃 = 0.99), height (1.8 ± 0.1 versus 1.8 ± 0.1m,
𝑃 = 0.98), BMI (27.9 ± 4.6 versus 27.8 ± 4.6 kg/m2, 𝑃 =
0.98), % fat (26.7 ± 8.5 versus 26.7 ± 8.5%, 𝑃 = 0.97), ASM
(28.6±4.3 versus 28.6±4.3 kg,𝑃 = 0.83), SMI (9.1±1.1 versus
9.1±1.1 kg/m2,𝑃 = 0.85), and grip strength (52.2±10.8 versus
51.6 ± 11.1, 𝑃 = 0.68). For the older group, from the FAMAS
and NWAHS cohorts, there were 784 men and 521 women
(Figure 1). 173 men and 146 women were excluded because
of incomplete data. Consequently, the final cohort consisted
of 611 men and 375 women. Women in the original cohort
were significantly older than the women in the final cohort
(74.0±6.3 versus 73.2±6.0 years,𝑃 = 0.05). No age difference
was noted formen (73.0±6.0 versus 72.7±5.7 years,𝑃 = 0.30).
There were no statistically significant differences between the
original and final cohort in terms of weight (81.8±13.6 versus
81.8 ± 13.3 kg, 𝑃 = 0.96), height (1.7 ± 0.1 versus 1.7 ± 0.1
years, 𝑃 = 0.85), BMI (27.9 ± 4.3 versus 27.9 ± 4.2 kg/m2,
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Table 1: Characteristics of subjects from the younger reference group and older adults (aged ≥ 65) in the NWAHS and FAMAS included in
the analysis.
Characteristics
Younger reference population Older study population















Age (SD), years 35.5 (5.3) 31.2 (7.3) 0.01 72.7 (5.7) 73.2 (6.0) 0.21
Weight (SD), kg 87.7 (15.9) 69.3 (15.3) <0.001 81.8 (13.3) 69.4 (12.4) <0.001
Height (SD), m 1.8 (0.1) 1.7 (0.1) <0.001 1.7 (0.1) 1.6 (0.1) <0.001
BMI (SD), kg/m2 27.8 (4.6) 25.5 (5.5) 0.03 27.9 (4.2) 27.8 (4.7) 0.79
% Fat 26.7 (8.5) 29.9 (11.6) 0.22 28.6 (6.9) 40.2 (6.9) <0.001
ASM (SD), kg 28.6 (4.3) 18.4 (4.1) <0.001 24.0 (3.2) 16.1 (2.4) <0.001
SMI (SD), kg/m2 9.1 (1.1) 6.7 (1.2) <0.001 8.2 (0.9) 6.4 (0.8) <0.001
Chronic conditions % % % %
Cardiovascular Disease 1.7 0.0 0.54 24.1 17.8 0.019
Diabetes 1.7 0.0 0.54 24.4 19.1 0.050
Hypertension 27.6 4.5 0.02 77.3 69.7 0.007
Hypercholesterolemia 44.7 13.6 0.06 31.1 50.3 <0.001
Arthritis 0.9 0.0 0.66 33.7 61.5 <0.001
Number of prescribed
medications
0 92.2 54.5 <0.001 15.1 6.3 0.02
1–3 7.8 45.5 37.1 39.7
4–6 0.0 0.0 25.8 32.9
≥7 0.0 0.0 22.0 21.1
SMI, skeletal muscle index; ASM, appendicular skeletal muscle mass; BMI, body mass index; SD, standard deviation; NS, not significant (𝑃 > 0.05); NA,
not applicable; cardiovascular disease, ischemic heart disease, acute myocardial infarction, stroke, and angina; diabetes, self-reported, Dr diagnosed, FPG ≥
7.0mmol/L, or HbA1c ≥ 6.5%; hypertension, BP ≥ 140/90, or already on treatment; hypercholesterolaemia, serum total cholesterol ≥5.5mmol/L; arthritis, self-
reported osteo- or rheumatoid.
𝑃 = 0.88), % fat (28.6 ± 6.9 versus 28.6 ± 6.9%, 𝑃 = 0.95),
ASM (23.9±3.3 versus 24.0±3.2 kg, 𝑃 = 0.92), SMI (8.2±0.9
versus 8.2±0.9 kg/m2,𝑃 = 0.94), and grip strength (37.2±8.9
versus 37.6 ± 8.9 kg, 𝑃 = 0.37).
Table 1 shows the characteristics of participants in the
final cohort aged 18–40 and aged 65 years and older. Compar-
ing men to women in the younger reference group, men were
significantly older (35.5±5.3 versus 31.2±7.3 years,𝑃 = 0.01),
heavier (87.7 ± 15.9 versus 69.3 ± 15.3 kg, 𝑃 < 0.001), and
taller (1.8 ± 0.1 versus 1.7 ± 0.1m, 𝑃 < 0.001) and had
higher BMI (27.8 ± 4.6 versus 25.5 ± 5.5 kg/m2, 𝑃 = 0.03)
and SMI (9.1 ± 1.1 versus 6.7 ± 1.2 kg/m2, 𝑃 < 0.001) than
women. Similar to the younger population group, older men
were significantly heavier (81.8 ± 13.3 versus 69.4 ± 12.4 kg,
𝑃 < 0.001), and taller (1.7 ± 0.1 versus 1.6 ± 0.1m, 𝑃 < 0.001)
andwith higher values forASM (24.0±3.2 versus 16.1±2.4 kg,
𝑃 < 0.001) and SMI (8.2 ± 0.9 versus 6.4 ± 0.8 kg/m2, 𝑃 <
0.001) than women. Interestingly, there was no difference in
the BMI (27.9±4.2 versus 27.8±4.7 kg/m2,𝑃 = 0.79) between
the older men and women. The spread of various chronic
conditions was shown in Table 1 with higher prevalence of
chronic conditions amongst the older population compared
to the younger population.
In men, low grip strength (Table 2) was noted in approx-
imately 14% of men aged between 65 and less than 80 years
and almost half of men aged 80 years and older. A higher
proportion of women (i.e., 33.5%) between 65 years and
less than 80 years had low grip strength compared to men.
Similarly, 63% of women aged 80 years and older had low grip
strength and this was higher in proportion within the same
age group of men.
The cut-off points (Table 2) for lowmusclemass identified
were as follows:
(a) <6.89 kg/m2 for men and <4.32 kg/m2 for women by
Baumgartner’s method;
(b) <7.36 kg/m2 for men and <5.81 kg/m2 for women by
the 20% gender specific method;
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Table 2: The prevalence of low muscle mass and low grip strength in the North West Adelaide Health Study (NWAHS) and Florey Adelaide
Male Ageing Study (FAMAS) based upon dual absorptiometry X-ray assessments of appendicular skeletal muscle mass.
Low grip strength (𝑛%) Low SMI (𝑛%) Low SMI (𝑛%) Low SMI (𝑛%)
EWGSOP Criteria [6]











mass adjusted for fat
and height (FAMAS
and NWAHS)
NWAHS + FAMAS men
Cut-offs <30Kg <6.89Kg/m2 <7.36Kg/m2 <−2.15 Kg
65 −< 80 (𝑛 = 540) 78 (14.4) 38 (7.0) 92 (17.0) 101 (18.7)
80+ (𝑛 = 71) 32 (45.1) 9 (12.7) 29 (40.8) 21 (29.6)
Total 65+ (𝑛 = 611) 110 (18.0) 44 (7.2) 121 (19.8) 122 (20)
NWAHS female
Cutoffs <20.0 Kg <4.32 Kg/m2 <5.81 Kg/m2 <−1.42 Kg
65 −<80 (𝑛 = 313) 105 (33.5) 0 (0) 56 (17.9) 63 (20.1)
80+ (𝑛 = 62) 39 (62.9) 1 (1.6) 18 (29) 12 (19.4)
Total 65+ (𝑛 = 375) 144 (38.4) 1 (1.6) 74 (19.7) 75 (20)
(c) <−2.15 formen and<−1.42 for women using the linear
regression method. The linear regression model was
ASM (kg) = −18.24 + 23.09 × height (m) + 0.11 × total
fat mass for men and ASM (kg) = −15.84 + 18.18 ×
height (m) + 0.11 × total fat mass for women.
The prevalence of lowmuscle mass ranged between 7 and
18% for men aged between 65 and 80 years but increased
to between 12 and 29.6% for men aged 80 years and older
(Table 2). However, for women, there was no increase in the
reported prevalence with increasing age with the prevalence
of low muscle mass ranging from 0 to 20.1% in those aged
between 65 and <80 years and remaining between 1.6–19.4%
in those aged 80 years and older. The prevalence reported by
the 20%gender specificmethod and linear regressionmethod
was similar andmuch higher than the prevalence reported by
Baumgartner’s method.
Figure 2 shows that the prevalence of sarcopenia was
higher in men (7–19.7%) and women (1.6–22.6%) aged 80
years and older compared to men (1.9–5.0%) and women
(2.5–7.0%) aged between 65 and <80 years. The prevalence of
sarcopenia in people aged 65 years and older in this study was
between 2.5% and 6.4% for men and between 0.3% and 9.3%
for women.The overall prevalence of sarcopenia as estimated
by Baumgartner’smethod, the lowest 20%method, and linear
regression method was 1.6%, 7.4%, and 7.2%, respectively.
4. Discussion
The key finding from this study is that in combination
with grip strength, different methods of determining low
muscle mass result in different sarcopenia prevalence. The
cut-off points for low muscle mass derived by the gender
specific lowest 20%method and the linear regressionmethod
yielded similar prevalence rates for low muscle mass and
sarcopenia. Also, the cutoffs generated by these twomethods,
in this study, were similar to those reported by EWGSOP
[1]. However, the cutoffs derived by the Baumgartner method
(<6.89 kg/m2 for men and <4.32 kg/m2 for women), in
this study, were much lower than that previously reported
(<7.26 kg/m2 for men and <5.50 kg/m2 for women) [2]. Our
findings of a lower cutoff than that previously reported
was similarly noted in an Australian study of women
(<4.85 kg/m2) [10]. Researchers from Korea have recently
reported similar SMI cut-off values (6.58 kg/m2 for men
and 4.59 kg/m2 for women) [17]. The mean ASM for the
younger reference population in this study was lower than
that reported in the Baumgartner (28.6 kg versus 30.6 kg for
men and 18.4 kg versus 20.9 kg) study and this is potentially
contributing to the difference in the reported cut-off values
[2]. Importantly, the sample size making up the younger
reference population in our study was small and so there is a
need to derive cutoffs from a larger cohort of younger people
before firm conclusions can be reached.
Using the lowest 20% method and linear regression
method to define lowmusclemass, the prevalence of sarcope-
nia reported in this study was approximately 6.2% for men
and 9%ofwomen aged 65 years. To the best of our knowledge,
there has only been one other Australian study which used
the lowest 20% method to define low muscle mass [9]. In
that study, the overall sarcopenia prevalence rate was 5% [9].
We observed a higher overall prevalence rate at 7.6% and
this is likely due to older age group in our study population
compared with the population in the other Australian study
(72.7±5.7 versus 61.7±7.1 years in men and 73.2±6.0 versus
61.0 ± 6.8 years in women) [9].
Consistent with other studies, the prevalence of low
muscle mass increased with age in men and was higher in
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Men Women Men Women Men Women
SMI reference of younger group
(FAMAS and CASA) + low grip
strength
Gender specific lowest 20%
(FAMAS and NWAHS) + low grip (FAMAS and NWAHS) + low grip
strength
Residuals of linear regression
strength
1.9% 0.0% 4.4% 6.7% 5.0% 7.0%
7.0% 1.6% 19.7% 22.6% 16.9% 16.1%












SMI: skeletal muscle index
Figure 2: Comparison of prevalence rate of sarcopenia as defined by EWGSOP, by using different methods of SMI cut points derivation with
a low grip strength (<30 kg for men and <20 kg for women).
those aged 80 years and older compared to those between
65 and <80 years using all three methods [18]. However,
in women, this relationship was not seen with the linear
regressionmethod, which also accounts for fatmass. Fatmass
reduces with increasing age in women but not in men [19]. In
this study, the prevalence of low grip strength increased with
age in both men and women. A greater proportion of women
however met the criteria of low grip strength compared to
men in older age. It is well known that a decline in sex
hormones with increasing age (andropause and menopause)
contributes to decline in strength [20].
Both the FAMAS and the NWAHS cohorts did not
include subjects from residential care facilities where the
prevalence of sarcopenia is likely higher.The requirement for
subjects to attend a hospital based clinic also made it very
likely that frail individualsmay have been less likely to partici-
pate. Therefore, the reported prevalence in this study is likely
to be an underestimate of the true prevalence of sarcopenia
in the community. Subjects enrolled in these studies were
predominantly Caucasian and so the findings from this study
are not generalizable to the wider multicultural Australian
population. Ethnic specific cutoffs need to be determined and
future research including different ethnic population groups
is important.
5. Conclusion
To conclude, the prevalence of sarcopenia varies depending
on the method used to estimate the cut-off values for low
muscle mass. Therefore, a consensus is required to identify
the preferredmethod to define Sarcopenia.This will allow for
pooling of research data. However, sarcopenia is common in
the community. Given that sarcopenia is linked to morbidity
and costs [4], early recognition and intervention through
exercise and nutritional programs may contribute to healthy
ageing outcomes and so a reduction in health costs [21].
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